Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $13.7452W HIGH $46.82
Volume
1.39 M
Value Traded
35.94 M
Short % Float
25.24%
Days to Cover
5.0
-10.14%Week
-9.54%1 Month
-10.11%3 Month
+3.94%6 Month
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
5.83 B
EPS (TTM)
-0.61
P/E Ratio
-
Ent. Value
5.38 B
Total Shares
233.31 M
Float Shares
211.88 M
Insiders
9.19%
Institutions
67.08%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|
PoA blends historical approval base rates, trial design score and FDA review track record.
HIMS Catalyst Timeline
Dated clinical, regulatory and corporate events for Hims & Hers Health, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Hims & Hers Health, Inc.
2Total events
0Upcoming
0Tier-1 (high impact)
2026 to 2026Coverage
Past FDA Catalysts and PDUFA Decisions
How HIMS actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| No matching catalysts | ||||||
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
No drug pipeline
Hims & Hers Health, Inc. is a services and tools company (CRO, lab tools or healthcare services). The clinical trials it takes part in test other companies' drugs, so it has no drug pipeline of its own to score.
Clinical Trial Results
Readouts, endpoints and source filings for every HIMS program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Boughton SoleilOfficer (Chief Legal Officer) | Sell | -3,462 293,886 held | $27.60 | 10/28/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in HIMS
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| Casdin Capital, LLC | 1.2 % (9.1 %) | 24.27 M | 700.00 K |
Ownership Trends
HIMS Short Interest
Shares sold short, counted twice a month.
25.24%
Short % of Float
of tradable shares sold short
53.5M
Shares Sold Short
-2.4% vs prior count
5.0 High
Days to Cover
trading days of normal volume to buy every short share back
10.7M
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-06 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How HIMS ranks across every disease it competes in
Competitive Position is a premium feature
See how HIMS ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialHIMS News
-HIMS
Nov 5, 2026▼ -6.3%today
Hims & Hers Benefits Adds Grüns, Medjet, Tonal, and Viome for Whole-Body Health and Support When You Need It Most
Hims & Hers Health, Inc. announced the addition of four new partners to its Benefits program, expanding its offerings to support whole-body health. The new partners include Grüns, Medjet, Tonal, and Viome, bringing the total to 14 since the program's launch in March. These partnerships aim to enhance subscriber health, including support for weight loss.
Read more →-HIMS
Oct 21, 2026Hims Expands Testosterone Care with Injectable and Oral TRT, Its Largest Men’s Health Launch to Date
Hims & Hers Health, Inc. has launched new injectable and oral testosterone replacement therapies (TRT) for men. This marks the largest expansion of their men's health program since its introduction last September. The new options aim to provide eligible men with more effective treatments for low testosterone.
Read more →-HIMS
Oct 12, 2026Hims & Hers to Announce Third Quarter 2026 Financial Results on November 9, 2026
Hims & Hers Health, Inc. will announce its third quarter 2026 financial results on November 9, 2026, after market close. A live conference call is scheduled for the same day at 5:00 p.m. ET, providing an opportunity for discussion of the results. Participants can join via designated phone numbers.
Read more →-HIMS
Oct 12, 2026Hers Launches in Australia, Built to Care for the Whole Woman
Hims & Hers launched Hers in Australia, offering personalized women's health care. The platform includes innovative treatments for hair regrowth, menopause, and weight management. It emphasizes comprehensive support and access to a Care Team available 24/7. This launch builds on the company's previous expansion efforts in North America and Europe.
Read more →-HIMS
Oct 7, 2026▼ -5%on this newsshared move
Hims & Hers Names Jon Franklin as Chief Accounting Officer
Hims & Hers Health, Inc. has appointed Jon Franklin as Chief Accounting Officer. Franklin, a CPA with extensive experience in technical accounting, will lead the company's accounting organization and report to CFO Yemi Okupe. This strategic hire is expected to bolster the company's financial oversight and infrastructure.
Read more →-HIMS
Oct 6, 2026Hims & Hers Health (NYSE: HIMS) Faces Securities Fraud Class Action After FTC Lawsuit Reveal Drives Stock Sharply Lower
Hims & Hers Health is facing a securities class action lawsuit following a complaint from the FTC that accuses the company of serious business misconduct. The allegations include improper sharing of consumer health data and misleading billing practices. As a result, Hims' stock plummeted by 14.7%, significantly impacting its market capitalization.
Read more →-HIMS
Oct 1, 2026Hims & Hers Names Chief Medical Officers in the UK and Australia, Deepening its Investment in Local Clinical Leadership
Hims & Hers Health, Inc. has appointed Kultar Garcha as Chief Medical Officer for the UK and EMEA, and Matt Vickers as Chief Medical Officer for Australia. These appointments aim to enhance local clinical leadership and improve health services in these regions. The move reflects the company's commitment to investing in global health and wellness.
Read more →-HIMS
Aug 31, 2026Hims Arrives in Australia, Bringing Personalised Care for Men Nationwide
Hims & Hers has officially launched its brand in Australia, rebranding the existing Pilot platform. The transition allows Australian men to access personalized care for health issues like sexual health, weight loss, and hair loss. The service now offers 24/7 access and retains existing patient-provider relationships, enhancing overall care.
Read more →-HIMS
Aug 31, 2026Hims Enters Australia, Marking First Expansion into the Asia-Pacific Market
Hims & Hers Health, Inc. has officially entered the Australian market, marking its first expansion into the Asia-Pacific region. This move follows the acquisition of Eucalyptus and includes the rebranding of Eucalyptus' men's health platform, Pilot, to the Hims brand. This strategic step is aimed at broadening Hims' global reach.
Read more →-HIMS
Aug 10, 2026Hims & Hers Health, Inc. Reports Second Quarter 2026 Financial Results
Hims & Hers Health, Inc. reported its financial results for Q2 2026, showcasing a robust performance. The company highlighted its commitment to providing accessible healthcare to nearly 3 million users. The results reflect ongoing growth and a focus on delivering quality health experiences at competitive prices.
Read more →-HIMS
Aug 6, 2026▼ -6.3%on this newsshared move
Hims & Hers Introduces New Hers App with First-of-Its-Kind, Doctor-Led, AI-Native Care Experience
Hims & Hers launched a new Hers app featuring an AI-native care experience for women. This app provides personalized weight loss support, integrating real-time data and direct communication with healthcare providers. The introduction of a smart scale enhances the user experience by syncing weight and progress data automatically. This initiative aims to make healthcare more proactive and tailored to individual needs.
Read more →-HIMS
Jul 29, 2026Hims & Hers Responds to FTC Lawsuit
Hims & Hers Health, Inc. has responded to a lawsuit filed by the FTC, claiming the lawsuit disregards evidence provided during a lengthy investigation. The company argues that the FTC's actions misinterpret telehealth laws and are aimed at generating negative publicity rather than protecting consumers. Hims & Hers asserts that the lawsuit is unfounded and misleading.
Read more →-HIMS
Jul 17, 2026Hims & Hers Chief Accounting Officer, Irene Becklund, Announces Departure from the Company
Hims & Hers Health, Inc. announced the departure of Chief Accounting Officer Irene Becklund, effective October 9, 2026, after over seven years with the company. Becklund will aid in the transition as an advisor for several months. The company is beginning a search for her permanent successor, with CFO Yemi Okupe taking on her responsibilities temporarily.
Read more →-HIMS
Jul 13, 2026Hims & Hers to Announce Second Quarter 2026 Financial Results on August 10, 2026
Hims & Hers Health, Inc. will announce its second quarter 2026 financial results on August 10, 2026, after market close. A live conference call is scheduled for the same day at 5:00 p.m. ET to discuss these results. Participants can join via specific dialing instructions provided.
Read more →-HIMS
Jun 2, 2026Hims & Hers Completes Acquisition of Eucalyptus, Advancing its Position as the World’s Largest Consumer Health Platform
Hims & Hers has successfully completed the acquisition of Eucalyptus, reinforcing its status as the largest consumer health platform globally. This strategic move is expected to enhance their service offerings and market presence. The acquisition reflects Hims & Hers' commitment to expanding its portfolio in the consumer health sector.
Read more →-HIMS
May 28, 2026Hims & Hers Expands Benefits for Active Subscribers With Eight New Health and Wellness Partners
Hims & Hers has announced the expansion of benefits for its active subscribers by partnering with eight new health and wellness providers. This initiative is designed to enhance the overall health offerings available to subscribers, aiming to improve their satisfaction and engagement with the platform.
Read more →-HIMS
May 21, 2026Hims & Hers Brings First-Time Access to Generic Semaglutide to Canada
Hims & Hers has announced the introduction of generic Semaglutide to the Canadian market, marking a significant step in expanding access to this medication. This initiative aims to provide more affordable treatment options for patients managing conditions such as obesity and diabetes. The availability of generics is expected to benefit consumers by reducing costs.
Read more →-HIMS
May 21, 2026Hims & Hers Expands GLP-1 Offering in Canada with Generic Semaglutide
Hims & Hers has expanded its GLP-1 offering in Canada by introducing a generic version of semaglutide. This move aims to enhance accessibility for patients seeking treatment options. The expansion reflects the company's commitment to providing affordable healthcare solutions.
Read more →-HIMS
May 19, 2026Hims & Hers Health, Inc. Prices Upsized $350 Million Convertible Senior Notes Offering to Support International Expansion and Accelerate AI-Driven Platform Investment
Hims & Hers Health, Inc. has announced an upsized offering of $350 million in convertible senior notes. The funds will be used to support the company's international expansion and enhance its AI-driven platform. This move reflects the company's commitment to growth and innovation in the healthcare sector.
Read more →-HIMS
May 18, 2026▼ -11%on this newsshared move
Hims & Hers Health, Inc. Announces Proposed Convertible Senior Notes Offering to Support International Expansion and Accelerate AI-Driven Platform Investment
Hims & Hers Health, Inc. has announced a proposed offering of convertible senior notes. The funds are intended to support the company's international expansion and enhance investments in its AI-driven platform. This move reflects the company's strategic focus on growth and technology integration.
Read more →About Hims & Hers Health, Inc.
Headquarters2269 CHESTNUT ST, SAN FRANCISCO, CA, 94123
BIOPHARMAWATCH ELITE PLUS
Trade the next HIMS catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime